Molecular profiling of inflammatory breast cancer: Identification of a poor-prognosis gene expression signature

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6789-6795

  Bièche, Ivan ^a,b   Lerebours, Florence ^a   Tozlu, Sengül ^a   Espie, Marc ^c   Marty, Michel ^d   Lidereau, Rosette ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BETA CHEMOKINE; CHEMOKINE CC LIGAND 5; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR; EPIREGULIN; GROWTH FACTOR; MESSENGER RNA; PROTEIN B FOS; PROTEIN B JUN; PROTEIN C JUN; PROTEIN FOS; PROTEIN MIP1A; PROTEIN MYCN; PROTEIN ROBO2; PROTEIN SNAIL1; RANTES; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; SONIC HEDGEHOG PROTEIN; THROMBOXANE A2 RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA FINGERPRINTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RARE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 6044230918     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0306     Document Type: Article

References (31)

1. Chang S, Parker SL, Pham T, Buzdar AU, Bursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-72.
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
3. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-9.
4. Turpin E, Bieche I, Bertheau P, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593-97.
5. van Golen KL, Davies S, Wu ZF, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999;5:2511-19.
6. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003;88:718-25.
7. Alpaugh ML, Tomlinson JS, Shao Z-M, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999;59:5079-84.
8. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-51.
9. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
10. Paradis V, Bieche I, Dargere D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003;163:733-41.
11. Latil A, Bieche I, Chene L, et al. A four gene expression model predicts recurrence in patients with clinically localized prostate cancer. Clin Cancer Res 2003;9:5477-85.
12. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56.
13. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001;61:1652-8.
14. Kruskal WH, Wallis WA. Use of ranks on one-criterion variance analysis. J Am Stat Assoc 1952;47:583-621.
15. Mann H, Whitney D. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
16. Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
17. Didier G, Brezellec P, Remy E, Henaut A. GeneANOVA-gene expression analysis of variance. Bioinformatics 2002;18:490-1.
18. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003;8:141-8.
19. Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer (Phila) 1989;64:1922-7.
20. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001;20:2401-12.
21. Park JM, Adam RM, Peters CA, et al. AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. Am J Physiol 1999;277:C294-301.
22. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003;278:37637-47.
23. Chiariello M, Marinissen MJ, Gutkind JS. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol 2000;20:1747-58.
24. Schuringa JJ, Timmer H, Luttickhuizen D, Vellenga E, Kruijer W. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 response element (IRE). Cytokine 2001;14:78-87.
25. Mendelson KG, Contois L-R, Tevosian SG, Davis RJ, Paulson KE. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci USA 1996;93:12908-13.
26. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355-61.
27. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
28. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
29. Villavicencio EH, Walterhouse DO, Iannaccone PM. The sonic hedgehog -patched-gli pathway in human development and disease. Am J Hum Genet 2000;67:1047-54.
30. Thayer SP, Di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (Lond) 2003;425:851-6.
31. Oliver TG, Grasfeder LL, Carroll AL, et al. Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA 2003;100:7331-6.